Recent and anticipated novel drug approvals (2Q 2025 through 1Q 2026).

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists Pub Date : 2025-06-03 DOI:10.1093/ajhp/zxaf147

Matthew H Rim, Collin Dean, Enela Aliaj, Matthew Dandino, Tyler Howse, Andrew M Levitsky

{"title":"Recent and anticipated novel drug approvals (2Q 2025 through 1Q 2026).","authors":"Matthew H Rim, Collin Dean, Enela Aliaj, Matthew Dandino, Tyler Howse, Andrew M Levitsky","doi":"10.1093/ajhp/zxaf147","DOIUrl":null,"url":null,"abstract":"Purpose: Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing updates on new and anticipated novel drug approvals.Summary: Selected drug approvals anticipated in the 12-month period covering the second quarter of 2025 through the first quarter of 2026 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from 58 novel drugs awaiting US Food and Drug Administration (FDA) approval. This year's pipeline features novel therapies for rare diseases, targeted cancer treatments, and new agents for various diseases states.Conclusion: Novel therapies continue to strengthen the current drug pipeline.","PeriodicalId":520552,"journal":{"name":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/ajhp/zxaf147","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing updates on new and anticipated novel drug approvals.

Summary: Selected drug approvals anticipated in the 12-month period covering the second quarter of 2025 through the first quarter of 2026 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from 58 novel drugs awaiting US Food and Drug Administration (FDA) approval. This year's pipeline features novel therapies for rare diseases, targeted cancer treatments, and new agents for various diseases states.

Conclusion: Novel therapies continue to strengthen the current drug pipeline.

查看原文本刊更多论文

近期和预期的新药批准（2025年第二季度至2026年第一季度）。

目的：卫生系统药剂师在监测药物管道管理处方、分配资源和优化新疗法的临床规划方面发挥着至关重要的作用。本文旨在通过提供新的和预期的新药批准的更新来支持药剂师。摘要：对2025年第二季度至2026年第一季度的12个月期间预计批准的选定药物进行审查。该分析强调了预计对医院和诊所产生重大临床和财务影响的药物，这些药物是从等待美国食品和药物管理局（FDA）批准的58种新药中选出的。今年的候选药物包括针对罕见疾病的新疗法、针对癌症的靶向治疗以及针对各种疾病的新药。结论：新疗法继续加强现有药物管道。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

自引率

0.00%

发文量